Skip to content
10-Q

Quarterly Report

BICYCLE THERAPEUTICS PLC BCYC

0001104659-26-052117

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 69.68M sh
Shares Diluted Q1 2026 · Mar 31, 2025 69.2M sh
Capex Q1 2026 · Mar 31, 2026 $713K
Capex Q1 2026 · Mar 31, 2025 $604K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$65.93M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$86.37M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $559.47M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $628.11M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $792.97M
Stockholders Equity Q1 2026 · Mar 31, 2026 $554.32M
Stockholders Equity Q1 2026 · Dec 31, 2025 $609.98M
Stockholders Equity Q1 2026 · Mar 31, 2025 $740.33M
Stockholders Equity Q1 2026 · Dec 31, 2024 $793.06M
Current Liabilities Q1 2026 · Mar 31, 2026 $48.89M
Current Liabilities Q1 2026 · Dec 31, 2025 $56.98M
Total Liabilities Q1 2026 · Mar 31, 2026 $98.08M
Total Liabilities Q1 2026 · Dec 31, 2025 $107.62M
Current Assets Q1 2026 · Mar 31, 2026 $619.14M
Current Assets Q1 2026 · Dec 31, 2025 $682.89M
Total Assets Q1 2026 · Mar 31, 2026 $652.4M
Total Assets Q1 2026 · Dec 31, 2025 $717.6M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.87
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.88
Eps Basic Q1 2026 · Mar 31, 2026 −$0.87
Eps Basic Q1 2026 · Mar 31, 2025 −$0.88
Sga Expense Q1 2026 · Mar 31, 2026 $17.47M
Sga Expense Q1 2026 · Mar 31, 2025 $21.12M
Rd Expense Q1 2026 · Mar 31, 2026 $48.9M
Rd Expense Q1 2026 · Mar 31, 2025 $59.06M
Net Income Q1 2026 · Mar 31, 2026 −$60.83M
Net Income Q1 2026 · Mar 31, 2025 −$60.75M
Operating Income Q1 2026 · Mar 31, 2026 −$65.48M
Operating Income Q1 2026 · Mar 31, 2025 −$70.2M
Revenue Q1 2026 · Mar 31, 2026 $887K
Revenue Q1 2026 · Mar 31, 2025 $9.98M